[go: up one dir, main page]

MX2019000271A - Anticuerpos humanizados que transmigran a traves de la barrera hematoencefalica y usos de los mismos. - Google Patents

Anticuerpos humanizados que transmigran a traves de la barrera hematoencefalica y usos de los mismos.

Info

Publication number
MX2019000271A
MX2019000271A MX2019000271A MX2019000271A MX2019000271A MX 2019000271 A MX2019000271 A MX 2019000271A MX 2019000271 A MX2019000271 A MX 2019000271A MX 2019000271 A MX2019000271 A MX 2019000271A MX 2019000271 A MX2019000271 A MX 2019000271A
Authority
MX
Mexico
Prior art keywords
barrier
humanized antibodies
hematenephallic
transmigrate
antibodies
Prior art date
Application number
MX2019000271A
Other languages
English (en)
Other versions
MX389765B (es
Inventor
Sulea Traian
Stanimirovic Danica
KEMMERICH Kristin
Durocher Yves
Original Assignee
Nat Res Council Canada
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Res Council Canada filed Critical Nat Res Council Canada
Publication of MX2019000271A publication Critical patent/MX2019000271A/es
Publication of MX389765B publication Critical patent/MX389765B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a anticuerpos y fragmentos de los mismos derivados por humanización de un anticuerpo existente, y a métodos para producirlos. Los anticuerpos humanizados de la presente invención muestran una unión potenciada al antígeno endotelial cerebral, una transmigración mejorada de un lado a otro de la barrera hematoencefálica, y una estabilidad térmica incrementada respecto al anticuerpo no humanizado de origen.
MX2019000271A 2016-07-06 2017-07-04 Anticuerpos humanizados que transmigran a traves de la barrera hematoencefalica y usos de los mismos. MX389765B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662358777P 2016-07-06 2016-07-06
PCT/IB2017/054036 WO2018007950A1 (en) 2016-07-06 2017-07-04 Humanized antibodies transmigrating the blood-brain barrier and uses thereof

Publications (2)

Publication Number Publication Date
MX2019000271A true MX2019000271A (es) 2019-08-21
MX389765B MX389765B (es) 2025-03-20

Family

ID=60912382

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019000271A MX389765B (es) 2016-07-06 2017-07-04 Anticuerpos humanizados que transmigran a traves de la barrera hematoencefalica y usos de los mismos.

Country Status (11)

Country Link
US (1) US10738115B2 (es)
EP (1) EP3481870A4 (es)
JP (1) JP7059494B2 (es)
KR (1) KR102406610B1 (es)
CN (1) CN109641970B (es)
AU (1) AU2017293450B2 (es)
BR (1) BR112019000220A2 (es)
IL (1) IL263937B2 (es)
MX (1) MX389765B (es)
NZ (1) NZ750244A (es)
WO (1) WO2018007950A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018109663A1 (en) 2016-12-12 2018-06-21 National Research Council Of Canada Antibody variants transmigrating the blood-brain barrier and uses thereof
JP7449092B2 (ja) * 2017-01-30 2024-03-13 ナショナル リサーチ カウンシル オブ カナダ 血液脳関門移動化合物及びその使用
EP3784701A4 (en) * 2018-04-24 2022-06-08 National Research Council of Canada THERAPEUTIC COMPOUNDS CROSSING THE BLOOD-BRAIN BARRIER AND THEIR USES
CA3100747A1 (en) 2018-05-18 2019-11-21 National Research Council Of Canada Antibodies and antibody fragments against hnav1.7 channel and their use in pain and cancer indications
BR112021008105A2 (pt) * 2018-10-29 2021-08-03 Biogen Ma Inc. variantes de fc5 humanizadas e estabilizadas para intensificação de transporte através de barreira hematoencefálica
WO2020201828A1 (en) 2019-04-05 2020-10-08 Tauc3 Biologics Limited Anti-tauc3 antibodies and uses thereof
JP2022528459A (ja) * 2019-04-05 2022-06-10 ビー － ポータル バイオロジクス、インコーポレイテッド 融合構築物及びその使用
KR20220133944A (ko) 2020-01-28 2022-10-05 위스콘신 얼럼나이 리서어치 화운데이션 인간 혈액-뇌 장벽 표적화 항체
EP4142737A4 (en) * 2020-04-27 2024-06-05 Aruna Bio, Inc. BINDING AGENTS AND USES THEREOF FOR CENTRAL NERVOUS SYSTEM DEPRESSION
CN111635457A (zh) * 2020-05-22 2020-09-08 上海药明生物医药有限公司 一种纳米抗体人源化的方法
CN114605539B (zh) * 2020-12-09 2024-01-02 南京融捷康生物科技有限公司 人源化的抗IL-4Rα单域抗体及其应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0711303B2 (en) 1993-07-30 2009-06-10 Affymax, Inc. Biotinylation of proteins
JP2000014383A (ja) * 1998-07-03 2000-01-18 Igaku Seibutsugaku Kenkyusho:Kk ヒト化抗体
WO2002057445A1 (en) 2000-05-26 2002-07-25 National Research Council Of Canada Single-domain brain-targeting antibody fragments derived from llama antibodies
JP4471656B2 (ja) 2001-11-30 2010-06-02 ナショナル リサーチ カウンシル オブ カナダ 新規自己集合分子
EP1452601A1 (en) 2003-02-28 2004-09-01 Roche Diagnostics GmbH Enhanced expression of fusion polypeptides with a biotinylation tag
US20090233357A1 (en) 2005-09-27 2009-09-17 Abedelnasser Abulrob Targeted Delivery of Compounds Using Multimerization Technology
US7744879B2 (en) * 2006-06-07 2010-06-29 Wisconsin Alumni Research Foundation Blood-brain barrier targeting antibodies
CA2796215C (en) 2010-04-14 2021-05-18 National Research Council Of Canada Compositions and methods for brain delivery of analgesic peptides
CN103619875B (zh) * 2011-01-28 2017-03-08 加拿大国家研究委员会 免疫球蛋白结构域的工程改造
PL2802606T3 (pl) * 2012-01-10 2018-09-28 Biogen Ma Inc. Udoskonalenie transportu cząsteczek terapeutycznych przez barierę krew-mózg
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
US10100117B2 (en) 2014-03-06 2018-10-16 National Research Council Of Canada Insulin-like growth factor 1 receptor-specific antibodies and uses thereof
LT3653644T (lt) 2014-03-26 2024-01-25 Julius-Maximilians-Universität Würzburg Monokloniniai antikūnai prieš augimo ir diferenciacijos faktorių 15 (gdf- 15), ir jų panaudojimas taikant vėžio kacheksijos ir vėžio gydymą

Also Published As

Publication number Publication date
CN109641970A (zh) 2019-04-16
BR112019000220A2 (pt) 2019-04-24
EP3481870A1 (en) 2019-05-15
JP2019525743A (ja) 2019-09-12
AU2017293450A1 (en) 2019-02-14
CA3029136A1 (en) 2018-01-11
JP7059494B2 (ja) 2022-04-26
US20190241653A1 (en) 2019-08-08
IL263937A (en) 2019-01-31
IL263937B2 (en) 2025-10-01
MX389765B (es) 2025-03-20
KR20190025954A (ko) 2019-03-12
IL263937B1 (en) 2025-06-01
CN109641970B (zh) 2022-11-18
NZ750244A (en) 2025-11-28
WO2018007950A1 (en) 2018-01-11
EP3481870A4 (en) 2020-03-11
KR102406610B1 (ko) 2022-06-08
US10738115B2 (en) 2020-08-11
AU2017293450B2 (en) 2024-08-08

Similar Documents

Publication Publication Date Title
MX2019000271A (es) Anticuerpos humanizados que transmigran a traves de la barrera hematoencefalica y usos de los mismos.
MX2024006675A (es) Anticuerpos monoclonales del receptor del factor de crecimiento 1 tipo insulina (igf-1r) y usos de los mismos.
CL2021000630A1 (es) Métodos para producir un anticuerpo anti-c5 (divisional de la solicitud no. 201701585)
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
EA201792589A1 (ru) Антитела против cd123 и конъюгаты указанных антител
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
DOP2018000259A (es) Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral
CO2020014343A2 (es) Anticuerpos específicos para cd3 y sus usos
MX2024006565A (es) Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos.
EA201791139A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
CO2018005436A2 (es) Anticuerpos y fragmentos de anticuerpo para la conjugación sitio-específica
BR112016014731A2 (pt) Anticorpos anti-baff
MX2017001597A (es) Anticuerpos anti-pd-l1.
EA201891339A1 (ru) Водный фармацевтический препарат, который содержит антитело к pd-l1 авелумаб
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
MX380937B (es) Anticuerpos dobles especificos.
ECSP17045736A (es) Composiciones y métodos para anticuerpos dirigidos a bmp6
MX373245B (es) Anticuerpos cd3 humanizados o quiméricos.
EA201792055A1 (ru) Антитела против cd48 и их конъюгаты
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
CR20150502A (es) Anticuerpos biespecíficos específicos para fap y dr5, anticuerpos específicos para dr5 y métodos de utilización
CY1125400T1 (el) Νεα αντι-ανθρωπινα αντισωματα gpvi και χρησεις αυτων
EA201791693A1 (ru) Гетеродимерные иммуноглобулины
AR100978A1 (es) LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
ZA201703510B (en) Antibodies, uses & methods